Nantes, France, June 6, 2023 – PROCOPE Medicals, designer of a fully implantable cardiac prosthesis, is proud to announce that it has already reached its minimum target of 400,000 euros in its fundraising campaign launched just 21 days ago. The fund-raising campaign is still underway and accessible on the Tudigo participative financing platform.
After more than five years of research and development, PROCOPE Medicals has embarked on the design of a compact, wireless total heart prosthesis offering natural pulsatility. Currently functional on an arterial simulator, the next key step will be to start in-vivo trials, marking a major advance towards market launch.
The aim of this fund-raising is to accelerate the development plan for our cardiac prosthesis in several key areas of research and development (R&D).
The first is the hemocompatibility study, with numerical simulations of ventricle hemodynamics to guarantee blood compatibility and optimize the performance of our device. Next, we will be pursuing the regulatory work required to obtain the necessary authorizations and certifications for trials and, ultimately, market access. We also plan to carry out a strategic study on the hybrid composite membrane, to optimize its durability. Recruiting new talent is also one of our objectives, to strengthen the R&D team and support the ramp-up of trials and studies.
PROCOPE Medicals remains determined to achieve its ultimate goal: to bring to market a cardiac prosthesis that is compatible with the majority of patients, and fully implantable to ensure optimal quality of life.
In vivo trials (preclinical and clinical) will begin in 2024, and market access is scheduled for 2030, paving the way for rapid sales growth. We invite all interested investors to participate in this investment opportunity and support our project.
For more information on our participatory fundraising and to invest in our startup, you can visit our page on the Tudigo !